Targeting the NRF2 pathway: A promising approach for corneal endothelial dysfunction

Curr Opin Pharmacol. 2024 Jan 2;74:102429. doi: 10.1016/j.coph.2023.102429. Online ahead of print.ABSTRACTMaintaining corneal endothelial function is required for vision, and corneal endothelial dysfunction is a major cause of visual deficits and blindness worldwide. To date there has been a dearth of innovation for therapeutics targeting the corneal endothelium. However, recent advances in understanding the role of oxidative stress and mitochondrial dysfunction have revealed potential avenues for the development of new therapies. This review summarizes recent developments in elucidating the role of the NRF2 pathway in corneal endothelial health and disease, focusing specifically on Fuchs' endothelial corneal dystrophy and the loss of corneal endothelial cells associated with cataract surgery. The pro-mitochondrial and antioxidant phenotype elicited by NRF2 activation offers a promising opportunity for new therapeutics for the diseased corneal endothelium.PMID:38171062 | DOI:10.1016/j.coph.2023.102429

Source: Current Opinion in Pharmacology - January 3, 2024 Category: Drugs & Pharmacology Authors: Keith W Ward Source Type: research